Conservative treatment for atypical endometrial hyperplasia: what is the most effective therapeutic method?
- PMID: 25045426
- PMCID: PMC4102730
- DOI: 10.3802/jgo.2014.25.3.164
Conservative treatment for atypical endometrial hyperplasia: what is the most effective therapeutic method?
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Comment on
-
Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia.J Gynecol Oncol. 2014 Jul;25(3):214-20. doi: 10.3802/jgo.2014.25.3.214. Epub 2014 Jul 3. J Gynecol Oncol. 2014. PMID: 25045434 Free PMC article. Clinical Trial.
References
-
- Anastasiadis PG, Skaphida PG, Koutlaki NG, Galazios GC, Tsikouras PN, Liberis VA. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. Eur J Gynaecol Oncol. 2000;21:131–134. - PubMed
-
- Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203:547.e1, 547.e10. - PubMed
-
- Lee TS, Seong SJ, Kim JW, Ryu HS, Song ES, Nam BH. Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2006) Jpn J Clin Oncol. 2011;41:817–819. - PubMed
-
- Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia: a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008;139:169–175. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
